Core Viewpoint - Recently, Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, successfully won bids for multiple core products in national and Guangdong alliance drug procurement, showcasing the company's market competitiveness and laying a solid foundation for future market expansion [1][2] Group 1: National Drug Procurement - Lai Mei Pharmaceutical's Nicorandil tablets (5mg) were selected in the 11th batch of national drug centralized procurement, marking a significant entry into the mainstream medical market by 2025 [1] - The selection of Nicorandil tablets will provide strong support for sales and meet broader clinical needs, injecting new momentum into Lai Mei Pharmaceutical's high-quality development [1] Group 2: Guangdong Alliance Drug Procurement - Lai Mei Pharmaceutical achieved success in multiple rounds of Guangdong alliance drug procurement, with selected products covering various fields including anti-infective drugs, specialty medications, and basic infusion solutions [1] - The successful procurement results for drugs like Clindamycin injection and Triptorelin acetate injection further demonstrate the company's strong performance in the market [1] - In the procurement for common and chronic disease medications, Lai Mei Pharmaceutical's Cefoperazone dry suspension (50mg) was also successfully selected, enhancing drug accessibility [2] Group 3: Company Strength and Market Impact - The dual breakthroughs in national and provincial procurement reflect Lai Mei Pharmaceutical's comprehensive strength [2] - The selection of multiple products in centralized procurement accelerates the clinical accessibility of quality drugs, benefiting a wider patient population and reinforcing the company's brand influence in niche markets [2]